
1. bmj case rep. 2018 mar 5;2018. pii: bcr-2017-223670. doi:
10.1136/bcr-2017-223670.

methylprednisolone-induced acute liver injury patient treated multiple
sclerosis relapse.

bresteau c(1), prevot s(2), perlemuter g(1), voican c(1).

author information: 
(1)department hepato gastroenterology nutirtion, hopital antoine-beclere, 
clamart, france.
(2)department pathology, hopital antoine-beclere, clamart, france.

drug-induced liver injury fourth common cause liver disease in
industrialised countries. methylprednisolone often considered a
treatment low hepatotoxicity. report case of
methylprednisolone-induced liver injury 35-year-old woman. admitted 
to department acute liver injury 2 months treatment high
dose methylprednisolone (1 g/day) multiple sclerosis relapse. other
cause liver injury could found (screening hepatotropic viruses,
autoimmune antibodies, ceruloplasmin, abdominal ultrasonography liver
biopsy). liver function tests spontaneously improved returned normal range
within 6 weeks. also performed brief review literature identified
12 cases methylprednisolone-induced liver injury patients treated for
multiple sclerosis relapse. immune rebound phenomenon could responsible for
rare true hepatotoxicity high-dose methylprednisolone therapy.

© bmj publishing group ltd (unless otherwise stated text article)
2018. rights reserved. commercial use permitted unless otherwise
expressly granted.

doi: 10.1136/bcr-2017-223670 
pmcid: pmc5847962
pmid: 29507031  [indexed medline]

conflict interest statement: competing interests: clement bresteau: none
declared. sophie prevot: none declared. gabriel perlemuter: reimbursement for
conferences abbvie, gilead, janssen servier; speaking consulting
fees biocodex, gilead, pilèje servier; royalties elsevier/masson,
john libbey solar. cosmin voican: reimbursement conferences gilead, 
biocodex, aptalis pharma, abbvie janssen; speaking fees gilead. .

